New data provide key mechanistic insights into how TG4050 induces and sustains potent, CD8+ T cell responses in operable HNSCC[*] patients Comprehensive immunogenicity data demonstrate TG4050’s ...
Working with the same tumor slices that pathologists use to diagnose and guide treatment of patients, however, Carstens can ...
Onchilles Pharma Publishes Landmark ELANE Pathway Study and Advances N17350 Toward the Clinic With New Financing and Leading Clinical Advisor ...
PURPOSE: We investigated the number, phenotype, and prognostic significance of CD8+ T cells in patients with mycosis fungoides (MF) and CD30− primary cutaneous large T-cell lymphoma (PCLTCL). PATIENTS ...
Intensity Therapeutics (INTS), with a ~$13M market cap, closed up nearly 395% Thursday after publishing phase 1/2 results on ...
Comprehensive immunogenicity data of individualized neoantigen therapeutic vaccine (INTV) TG4050, from the randomized Phase I study in operable ...
Combination with bispecific T-cell engagers amplifies T-cell recruitment and cytotoxic activity against tumor cells -- Düsseldorf, Germany, ...
Inflammatory arthritis resulting from immune checkpoint inhibitor use is immunologically unique and likely driven by T cells ...
Large granular lymphocytic leukemias (LGLLs) are a heterogeneous group of rare chronic lymphoproliferative disorders characterized by the clonal proliferation of cytotoxic lymphocytes. Among them, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback